The Human Genome Project
Sequencing Three Billion Bases and the Race to Finish
- 8 chapters
- 22m
- Biochemistry & Molecular Biology
- Free · no sign-up
The project's chapters cover its complex history, from early sequencing methods to the dramatic rivalry between the public consortium and Celera Genomics. They detail the technical challenges of shotgun versus clone-by-clone sequencing, the 2000 joint announcement, and the 2003 completion under the Bermuda Principles that ensured open data sharing.
This comprehensive guide explains how scientists achieved the impossible while navigating corporate competition and ethical questions about genetic information. Anyone interested in modern biology will find this essential reading for understanding one of science's greatest achievements.
Listen
-
Read this chapter
The Human Genome Project began in 1990 and lasted thirteen years, with the goal of figuring out the complete DNA sequence of the human genome. The idea of mapping disease genes to specific parts of chromosomes started with Ronald Fisher, whose work helped lead to the project. In 1977, Walter Gilbert, Frederick Sanger, and Paul Berg developed methods for sequencing DNA.
In May 1985, Robert L. Sinsheimer brought together scientists at University of California, Santa Cruz for a meeting about creating a reference genome through gene sequencing. Walter Gilbert later drafted the initial plan for what he named The Human Genome Institute during his flight home. The following March, Charles DeLisi and David Smith from the Department of Energy's Office of Health and Environmental Research convened the Santa Fe Workshop. Around the same time, Renato Dulbecco, who led the Salk Institute for Biological Studies, introduced the idea of sequencing an entire genome in an essay published in Science titled "A Turning Point in Cancer Research: Sequencing the Human Genome," though it stemmed from a longer proposal focused on genetic roots of breast cancer. Two months later, James Watson, one of the scientists who discovered DNA's double helix, hosted a workshop at Cold Spring Harbor Laboratory. The concept of building a reference genome thus emerged from three separate origins—Sinsheimer, Dulbecco, and DeLisi—and it was ultimately DeLisi's efforts that set the project in motion.
The Santa Fe Workshop, backed by a federal agency, set in motion a challenging path to turn the idea into U.S. public policy. In a memo to Assistant Secretary for Energy Research Alvin Trivelpiece, then-Director of the Office of Health and Environmental Research Charles DeLisi laid out a broad plan for the project. That kicked off a long and complex chain of events that led to approved reprogramming of funds, allowing the OHER to launch the project in 1986. DeLisi's proposal became the first line item in President Reagan's 1988 budget submission, which Congress ultimately approved. Senator Pete Domenici of New Mexico, a key figure whom DeLisi had befriended, played a major role in that approval. As chairman of the Senate Committee on Energy and Natural Resources and the Budget Committee, Domenici held influence over the DOE budget process. Congress also added a comparable amount to the NIH budget, officially beginning funding from both agencies.
Trivelpiece pursued approval for DeLisi’s proposal by presenting it to Deputy Secretary William Flynn Martin in the spring of 1986, alongside Under Secretary Joseph Salgado. He secured support from John S. Herrington to reprogram $4 million toward launching the project. This effort led to a proposed budget of $13 million included in the Reagan administration’s 1987 submission to Congress. The measure passed both Houses and set a timeline of fifteen years for completion.
In 1990, the U.S. Department of Energy and the National Institutes of Health agreed to work together on the Human Genome Project, setting its official start date for that year. At the time, David J. Galas was leading the Office of Biological and Environmental Research within the Department of Energy, while James Watson oversaw the NIH Genome Program. By 1993, Aristides Patrinos replaced Galas, and Francis Collins took over from Watson as head of the NIH National Center for Human Genome Research, which later became the National Human Genome Research Institute. A working draft of the genome was announced in 2000, with the full papers published in February 2001. A more complete version followed in 2003, and finishing work continued for over a decade after that.
The Human Genome Project began in 1990 when the US Department of Energy and the National Institutes of Health officially launched it, planning for a 15-year timeline. The effort brought together scientists from the United States, the United Kingdom, France, Australia, China, and other countries who joined the consortium. It ended up costing less than expected—about $2.7 billion, which equals roughly $5 billion in today’s money. Most of the genome was sequenced during a two-year period.
In 1974, Mark Skolnick at the University of Utah began searching for the location of the breast cancer gene. His work led to the development of a technique called restriction fragment length polymorphism, or RFLP. Skolnick collaborated with David Botstein, Ray White, and Ron Davis, who together conceived of a method to build a genetic linkage map of the human genome. This approach allowed scientists to identify where specific genes were located. The success of this gene mapping effort paved the way for the larger human genome project, making it possible to move forward with sequencing the entire genome.
In 2000, a rough draft of the human genome was finished and revealed to the world by US President Bill Clinton and British Prime Minister Tony Blair. The work was largely done by a team at the University of California, Santa Cruz, led by graduate student Jim Kent and his advisor David Haussler. After more sequencing followed, the nearly complete version of the genome was declared on 14 April 2003—two years ahead of schedule. Then, in May 2006, another major step toward finishing the project was reached.
-
Read this chapter
The Human Genome Project did not aim to read every letter of DNA inside human cells. It concentrated only on the parts known as euchromatic regions, which account for 92.1 percent of our genome. The rest—about 7.9 percent—resides in scattered areas like centromeres and telomeres. These sections are especially hard to decode, so they were left out of the original goals. That’s how the project balanced ambition with practicality.
The Human Genome Project reached a major milestone when it was officially declared complete in April 2003. A rough draft had been made available just a few years earlier, in June 2000, and by February 2001, scientists had published a working draft of the genome. The final sequencing map was released on April 14, 2003. At the time, it was reported that this version covered 99% of the euchromatic human genome with 99.99% accuracy. But a more detailed quality check, published on May 27, 2004, showed that over 92% of the sequence met that high standard, which aligned with the project’s original goal.
In March 2009, the Genome Reference Consortium released a more accurate version of the human genome, but even that update left over 300 gaps in the sequence. By 2015, 160 of those gaps still remained unfilled, showing how complex and incomplete the project had been despite major advances. The work continued, with scientists striving to close each remaining piece of the puzzle.
In May 2020, the Genome Reference Consortium reported 79 unresolved gaps in the human genome sequence, making up around 5 percent of the total. But just months after that, scientists using new long-range sequencing methods and a special cell line—derived from a hydatidiform mole where both chromosome copies are identical—achieved the first complete, telomere-to-telomere sequence of the human X chromosome. Several months later, the same approach yielded an end-to-end sequence for human autosomal chromosome 8.
In April 2022, the Telomere-to-Telomere consortium published a complete sequence of the non-Y chromosomes, revealing the 8% of the human genome that the Human Genome Project had missed. Using this new reference, the T2T consortium identified over 2 million additional genomic variants. Then in August 2023, Rhie and colleagues reported success in sequencing the previously missing regions of the Y chromosome, finally completing all 24 human chromosomes. The Y chromosome was the last to be fully sequenced because of its large number of repetitive elements—around 30 million base pairs, or about half its total length.
-
Read this chapter
The Human Genome Project has opened doors across many scientific fields, from medicine to evolution. By mapping the DNA, researchers can now identify mutations tied to cancer, design better medications, and predict how drugs will affect patients. The work also helps in fighting viruses by spotting specific genetic patterns, aids forensic science, and supports advancements in energy, farming, and animal breeding. It contributes to understanding human history through bioarcheology and anthropology, offering new insights into our past and future.
The DNA sequence is stored in public databases, like GenBank, which is managed by the US National Center for Biotechnology Information and similar groups in Europe and Japan. This database includes not just known gene sequences but also hypothetical ones. Other tools, such as the UCSC Genome Browser and Ensembl, offer extra data and visualization features to help researchers explore the information. Because the raw data is hard to read on its own, scientists have created computer programs to analyze it. The progress in genome sequencing has followed a pattern similar to Moore’s Law, where technology improves exponentially. By 2023, it was possible to sequence a whole genome in about five hours, though usually it still takes weeks.
-
Read this chapter
Identifying where genes begin and end in a DNA sequence is called genome annotation, and it falls under bioinformatics. Although expert biologists are the best at this work, it's slow, so computers are now widely used to keep up with the demands of sequencing projects. Starting in 2008, a new method called RNA-seq allowed scientists to directly sequence messenger RNA in cells. This replaced older techniques that depended on DNA sequence features, offering much greater accuracy. Today, annotating genomes like the human one relies heavily on deep sequencing of transcripts from every tissue using RNA-seq. These studies have shown that more than 90% of genes produce multiple splice variants, where exons are combined differently to create several gene products from a single location.
The Human Genome Project published a genome that doesn’t match everyone’s DNA. Instead, it’s based on a mix from a small group of anonymous donors of African, European, and East Asian descent. This reference sequence serves as a foundation for future research into individual genetic differences. Later efforts sequenced genomes from various ethnic groups, but by 2019, only one reference genome existed.
-
Read this chapter
The Human Genome Project began in 1990 with a bold aim: to map and understand all three billion base pairs that make up human DNA. This massive scientific effort was launched to uncover the genetic causes of disease and pave the way for new treatments. Known as a megaproject, it set out to decode the full human genetic instruction manual. The work involved identifying every single piece of the genetic code that defines us. It was not just about sequencing; it was about understanding how these instructions relate to health and illness. This project would ultimately reshape medicine and our knowledge of life itself.
The genome was divided into smaller sections, each about 150,000 base pairs long. These pieces were inserted into bacterial artificial chromosomes, or BACs, which are genetically modified versions of bacterial chromosomes. Once inside bacteria, the DNA replication machinery made copies of these vectors. Each small section was then sequenced on its own as part of a "shotgun" project and later put together. The larger chunks, each around 150,000 base pairs, were assembled to form chromosomes. This method is called the "hierarchical shotgun" approach because it starts with big pieces that are first mapped to chromosomes before being chosen for sequencing.
The Human Genome Project received funding from the US government through the National Institutes of Health, as well as the Wellcome Trust, a UK charity organization. Support also came from many other groups around the world. This funding helped large sequencing centers such as the Whitehead Institute, the Wellcome Sanger Institute—then known as The Sanger Centre, based at the Wellcome Genome Campus, Washington University in St. Louis, and Baylor College of Medicine.
The Human Genome Project included efforts to ensure that developing nations could participate, and UNESCO played a key role in making that happen. The organization helped connect researchers from around the world, supporting global involvement in mapping human DNA. This international cooperation was vital for the project’s success, as it brought together scientists from many countries. UNESCO's work made sure that knowledge and resources were shared widely, not limited to just a few advanced nations. By fostering this kind of collaboration, the project benefited from diverse perspectives and expertise across the globe. The inclusion of developing countries reflected a broader goal of scientific equity and shared discovery. UNESCO’s contribution was essential in building a more inclusive scientific community around the world.
-
Read this chapter
In 1998, Craig Venter launched a privately funded effort through his company Celera Genomics, aiming to sequence the human genome faster and cheaper than the publicly funded project. While the public Human Genome Project spent about $3 billion, Venter’s team invested $300 million and focused mainly on production sequencing and assembly. The publicly funded effort also supported mapping and sequencing other organisms like worms, flies, and yeast, as well as developing databases, new technologies, and bioinformatics programs. Both projects spent around $250 million on production sequencing, though Celera used publicly available maps from GenBank, which helped their work.
Celera took a different approach to sequencing the human genome, using a method called whole genome shotgun sequencing. This technique relied on pairwise end sequencing, which had previously been used to map bacterial genomes as large as six million base pairs. But this was the first time it would be attempted on a genome anywhere near the size of the human genome, which stretches three billion base pairs long.
Celera initially said it would try to patent just 200 to 300 genes, but then changed its plan to seek intellectual property protection on what it called "fully-characterized important structures," setting that target at 100 to 300 genes. Eventually, the company filed preliminary patent applications for 6,500 whole or partial genes.
In July 2000, the UCSC Genome Bioinformatics Group made the first working draft available online. Within the first day, scientists had downloaded around 500 gigabytes of data. This happened while Celera was still following the terms of the 1996 "Bermuda Statement," which required them to share their findings annually. Unlike the publicly funded effort, Celera did not allow free use or redistribution of their data. Because of this, the public project had to release its first draft earlier than Celera. The publicly funded team was also required to publish new data daily, while Celera only updated once a year.
In March 2000, President Bill Clinton and Prime Minister Tony Blair made a joint statement saying that anyone who wanted to study the genome sequence should have “unencumbered access” to it. That announcement hurt Celera's stock price, sending it down sharply and pulling down the whole biotechnology-heavy Nasdaq with it. The sector lost around fifty billion dollars in market value within just two days.
Although the working draft of the human genome was announced in June 2000, it wasn’t until February 2001 that Celera and the HGP scientists published their findings. Nature magazine, which featured the publicly funded project’s scientific paper, included special issues describing the methods used to create the draft sequence and offering analysis of the results. These early drafts covered about 83% of the genome, including 90% of the euchromatic regions but with around 150,000 gaps and many segments still not properly ordered or oriented. At that time, both groups claimed the project had been completed. Improved versions were later announced in 2003 and 2005, bringing the coverage to roughly 92% of the sequence.
-
Read this chapter
In the public-sector Human Genome Sequencing Consortium, researchers gathered blood from female donors or sperm from male donors to create DNA samples. Only a small number of these samples were actually used in the project, and to protect privacy, neither the donors nor the scientists knew whose DNA was being sequenced. Most of the work relied on DNA clones from many different libraries, with Pieter J. de Jong responsible for creating most of them. Over 70% of the reference genome came from a single anonymous male donor from Buffalo, New York, known by the code name RP11—where "RP" stands for Roswell Park Comprehensive Cancer Center.
The scientists working on the Human Genome Project used white blood cells from four donors—two male and two female—to create DNA libraries. These donors were randomly selected from a group of twenty each, and each contributed their own library, though one in particular, called RP11, was used more frequently due to its superior quality. Because of differences in sex chromosomes, male samples contained slightly less DNA from the sex chromosomes compared to females, since males have one X and one Y chromosome, while females have two X chromosomes. The remaining 22 pairs, known as autosomes, are identical in both sexes.
After the main sequencing of the Human Genome Project wrapped up, scientists kept working on understanding DNA differences through the International HapMap Project. This effort aimed to find patterns in single-nucleotide polymorphisms, called haplotypes or "haps." The project used DNA from 270 people total: Yoruba individuals from Ibadan, Nigeria; Japanese people in Tokyo; Han Chinese in Beijing; and a group from the French Centre d'Etude du Polymorphisme Humain, which included U.S. residents with Western and Northern European backgrounds.
In the Celera Genomics private-sector effort to sequence the human genome, scientists used DNA from five individuals. The lead scientist there was Craig Venter. He later admitted in a public letter to the journal Science that his own DNA had been part of a group of twenty-one samples. Of those, five were chosen for use in the project.
-
Read this chapter
With the sequence complete, scientists turned their attention to finding genetic differences tied to common illnesses such as cancer and diabetes. They needed to examine the data closely, searching for variations in DNA that could raise a person’s likelihood of getting sick. This effort aimed to uncover why some individuals develop certain conditions more often than others. The work went beyond simply mapping the genome; it sought to understand how genetic code functions in both health and disease. Researchers compared many individual sequences, looking for patterns associated with higher risks. These discoveries would later influence how doctors treat and prevent widespread diseases. The task demanded careful study of enormous amounts of information. Each base pair played a role in this search for understanding.
The Human Genome Project promised practical benefits for medicine and biotechnology, and those results began appearing even before the work was complete. Companies like Myriad Genetics started offering genetic tests that show predisposition to illnesses such as breast cancer, hemostasis disorders, cystic fibrosis, and liver diseases. Researchers also believe that understanding the genome will help with cancers, Alzheimer’s disease, and other conditions, possibly leading to major improvements in how they are managed in the future.
For biologists, the human genome database offers powerful tools. A researcher studying cancer, for example, might focus on a specific gene. By accessing the database online, they can review what other scientists have discovered about that gene—like its three-dimensional structure, function, evolutionary links to genes in mice, yeast, or fruit flies, harmful mutations, how it interacts with other genes, which body tissues activate it, and related diseases. This deeper knowledge of molecular processes may lead to new treatments. Since DNA is central to how cells work, expanding our understanding of it promises medical advances across many areas of clinical interest.
The Human Genome Project is revealing how DNA sequences from different species can shed light on evolution. Scientists are now able to approach evolutionary questions using molecular biology. Key events in evolution—like the rise of ribosomes and organelles, the formation of body plans in embryos, and the development of the vertebrate immune system—can be understood at the molecular level. This project is expected to clarify many differences and similarities between humans and other primates, as well as other mammals.
The Human Genome Project opened doors for genetic research beyond medicine, especially in agriculture. For instance, scientists studied Tritium aestivum, the most widely grown type of bread wheat, to understand how domestication changed the plant over time. By comparing wild and cultivated strains, they discovered which parts of the genome are most open to manipulation. This work is helping shape the future of crop development, potentially leading to wheat that’s healthier and more resistant to disease.
The Human Genome Project led to a new way of studying biology called systems biology, where scientists look at networks of genes and proteins instead of studying individual parts in isolation. In this field, researchers like Anton Yuryev have developed computational models and tools that combine genomic data with known biological interactions. This kind of work has helped identify regulatory networks, signaling pathways, and possible targets for drugs.
Read
Free to download, keep and share. For general information only — not professional medical, legal or financial advice. Please consult a qualified professional.